Phase II Study Of Neoadjuvant Chemotherapy With Gemcitabine, Oxaliplatin And Erlotinib (Gemoxt) In Borderline Resectable Pancreatic Adenocarcinoma.

Trial Profile

Phase II Study Of Neoadjuvant Chemotherapy With Gemcitabine, Oxaliplatin And Erlotinib (Gemoxt) In Borderline Resectable Pancreatic Adenocarcinoma.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 01 May 2009

At a glance

  • Drugs Erlotinib; Gemcitabine; Oxaliplatin
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 May 2009 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 24 Feb 2009 Additional lead trial centre identified as reported by ClinicalTrials.gov, last updated 24-Feb-2009.
    • 24 Feb 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top